Management Quality -- 8/10
David Rosa became CEO in July 2025 after a 30-year career at Intuitive, succeeding Gary Guthart
who moved to Executive Chairman. Under their combined leadership, the da Vinci 5 launch has been
near-flawless, manufacturing scaled to 870 dV5 placements in FY2025, and procedure growth guidance
has been consistently beaten -- a hallmark of an underpromise/overdeliver culture. Capital allocation
is conservative and shareholder-friendly: $2.3B in buybacks, $9B cash, zero debt.
Weight: 20%
CEO Transition
Rosa since Jul 2025
30-year veteran, joined 1996 as engineer
dV5 Placements (FY2025)
870
Of 1,721 total; up from 362 in FY2024
Buybacks (FY2025)
$2.3B
Average price ~$478/share
Cash / Debt
$9B / $0
Fortress balance sheet, zero leverage
Leadership Transition
New CEO
David J. Rosa
Joined Intuitive in 1996 as an engineer. Helped build the first da Vinci prototype.
Served as President since 2020. Appointed CEO in July 2025. This is an internal
succession from a 30-year veteran -- the strongest type of continuity for a
founder-led culture.
Executive Chairman
Gary Guthart
Transitioned to Executive Chairman in July 2025 after serving as CEO since 2010.
Oversaw the Xi platform era, international expansion, and the launch of Ion.
Remains actively involved in strategic oversight and board governance.
Internal succession preserves institutional knowledge and culture -- a best-in-class transition.
Da Vinci 5 Launch Execution
| Milestone |
Timeline Set |
Outcome |
Status |
| Limited launch (2024) |
Announced 2023 |
Delivered on schedule; 362 dV5 placed in FY2024 |
DELIVERED |
| Broad launch (mid-2025) |
Announced 2024 |
Delivered on schedule; manufacturing scaled |
DELIVERED |
| 870 dV5 placements in FY2025 |
Implied by ramp |
870 placed vs. 362 in FY2024 (+140%) |
DELIVERED |
| 10,000+ surgeons on dV5 |
Organic adoption |
Achieved by YE2025; validates training ecosystem |
DELIVERED |
| Force Feedback broad supply |
Expected late 2025 |
Supply remained limited; consistently communicated |
WATCH |
Near-flawless launch execution. Force Feedback supply was the only minor miss, consistently communicated.
Procedure Growth Guidance Accuracy
| Year |
Initial Guide |
Post-Q1 |
Post-Q2 |
Post-Q3 |
Actual |
Result |
| FY2024 |
13-16% |
-- |
-- |
-- |
17% |
BEAT |
| FY2025 |
13-16% |
15-17% (post-Q1) |
15.5-17% (post-Q2) |
17-17.5% (post-Q3) |
~18% |
BEAT |
Pattern of sandbagging early, then consistent raises throughout the year -- a hallmark of an
underpromise/overdeliver culture. FY2026 guidance of 13-15% follows the same playbook and
looks conservative given FY2025 delivered 18%.
International Expansion Execution
ab medica Acquisition
EUR 290M
Going direct in Italy, Spain, Portugal
Combined Population
118M
Significant greenfield opportunity
OUS Procedure Growth
23% FY2025
~35% of global volume, up from ~30%
Prior Direct Successes
UK, Germany
Proven playbook for going direct
The ab medica acquisition (expected close by end Q1 2026) brings Italy, Spain, and Portugal
under direct control. Management has successfully executed this playbook before in the UK and
Germany. Going direct improves service quality, accelerates surgeon training, and captures
distributor margin -- all of which support higher procedure volumes over time.
Capital Allocation
FY2025 Buybacks
$2.3B
Average ~$478/share
Cash and Investments
$9B
Fortress balance sheet
Total Debt
$0
Zero leverage, fully self-funded
FY2025 FCF
~$2.5B
Nearly doubled from ~$1.3B in FY2024
Conservative approach with strong FCF supporting both R&D investment and shareholder returns.
The $2.3B buyback program at ~$478/share average demonstrates willingness to return capital
while maintaining a debt-free balance sheet. With $9B in cash and investments, Intuitive has
ample flexibility for strategic M&A (like ab medica), continued R&D spending, and further
buybacks without any need for external financing.
Gross Margin Concern
Gross margins compressed ~150bps in FY2025 vs. FY2024 (67.6% vs. 69.1%) due to three
factors: (1) tariff headwinds, (2) new facility depreciation costs, and (3) higher-cost
dV5/Ion product mix. Management guided FY2026 gross margins at 67-68% (roughly flat) with
120bps of tariff headwinds baked in.
| Fiscal Year |
Non-GAAP Gross Margin |
| FY2021 |
71.2% |
| FY2022 |
69.2% |
| FY2023 |
68.1% |
| FY2024 |
69.1% |
| FY2025 |
67.6% |
| FY2026E |
67-68% |
The path back to 70%+ gross margins requires dV5 cost-downs and facility leverage -- achievable
but will take multiple years. Operating margins have expanded (37.4% in FY2025 vs. 36.7% in FY2024)
as the business scales, partially offsetting gross margin pressure.
Assessment
The CEO transition from Guthart to Rosa is the strongest type of succession: an internal 30-year veteran who helped build the original da Vinci prototype and served as President since 2020. There is no learning curve on product, culture, or strategy. Guthart remains engaged as Executive Chairman, providing continuity during the most critical phase of the dV5 launch cycle.
Execution on the da Vinci 5 launch has been near-flawless. Management set expectations for a limited launch in 2024 and broad launch by mid-2025, and delivered on both. Manufacturing scaled from 362 dV5 placements in FY2024 to 870 in FY2025 -- a 140% increase -- while maintaining quality and surgeon training throughput. The only minor miss was Force Feedback instrument supply, which remained constrained but was consistently communicated to investors.
The sandbagging pattern on procedure growth guidance is a feature, not a bug. Two consecutive years of guiding 13-16% and delivering 17-18% builds credibility and creates a reliable beat-and-raise cadence. International execution is strong: the ab medica acquisition extends a proven direct-market playbook to Southern Europe.
The one knock is gross margin compression. A 150bps decline in FY2025 with flat guidance for FY2026 means the path to recovery will be multi-year. While operating margins are expanding and FCF nearly doubled, investors focused on gross margin trajectory have a legitimate concern. Management needs to demonstrate dV5 cost-downs and facility leverage over the next 4-6 quarters.
Score Rationale
8.0/10. Best-in-class CEO succession from a 30-year internal veteran.
Near-flawless dV5 launch execution with manufacturing scaling 140% YoY. Consistent
procedure growth guidance beats demonstrate an underpromise/overdeliver culture. Capital
allocation is conservative and shareholder-friendly: $2.3B in buybacks, $9B cash, zero
debt. International expansion via ab medica follows a proven direct-market playbook.
Not a 9 because gross margins compressed 150bps in FY2025 with no near-term recovery
expected (FY2026 guided flat at 67-68%), and Force Feedback instrument supply lagged
the broader dV5 ramp. The multi-year path back to 70%+ gross margins introduces
execution risk that prevents a higher score.
Data sourced from
Daloopa, earnings call transcripts, and company disclosures.